anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After the purpose and method of the research are explained, a written informed consent form will be obtained and the Patient Introduction Form will be filled out. Mobile phone usage skills of patients undergoing hemodialysis treatment will be evaluated using the Digital Literacy Scale. Individuals in the initiative group will be given individual training on how to use the application through the application demo. Individuals in the initiative group will be given consultancy by the researcher while downloading the application and logging in with their username. Questionnaires and scale forms will be applied to the patients in the control group on the 0th day, the 14th day, and at the 1st, 2nd and 3rd months. Laboratory values and intradialytic weight information will be obtained from patient files.
PCT No. PCT/JP96/01867 Sec. 371 Date Jan. 5, 1998 Sec. 102(e) Date Jan. 5, 1998 PCT Filed Jul. 5, 1996 PCT Pub. No. WO97/03016 PCT Pub. Date Jan. 30, 1997The fine particles of peraloid porous hydroxyapatite are provided, which have an atomic ratio of Ca/P in a range of 1.62-1.72 and the chemical formula Ca5(PO4)3(OH). The particles are comprised of micropores having a petaloid porous structure not only on the surface but also in the inside of the particles, and have the specific particle diameter of the specific particle size, micropore diameter of the specific particle size, the specific surface of the specific range, static and pressurized percentage of voids of the specific range. The particles have superior dispersibility and are useful in the fields such as carriers for pharmaceuticals and so on, adsorbents, absorbents, sustained-release materials, filtering agents, biological materials, fillers for plastics, and anti-blocking agents for films and so on.
A multivalent vaccine composition that comprises a papaya mosaic virus (PapMV) component and one or more antigens is provided. The composition can further optionally comprise a  Salmonella spp . porin component. The PapMV component can be PapMV or PapMV virus-like particles (VLPs). The porin component can be a  Salmonella spp . OmpC, OmpF or a combination thereof, and can be combined with the PapMV component or conjugated to the PapMV component. The PapMV component in the multivalent vaccine composition functions as an adjuvant and/or an immunostimulant with respect to the one or more antigens. Use of the multivalent vaccine compositions to provide protection against a plurality of strains of a pathogen, or against more than one pathogen, are also provided.
PURPOSE: Sinus thrombosis is a common post-operative finding after posterior fossa surgery performed in the vicinity of the dural venous sinuses. The SARS-CoV-2 virus has been shown to confer an increased risk of venous thromboembolic events owing to eliciting a hyper-inflammatory and pro-thrombotic state. In this study, we examine the incidence of post-operative venous sinus thrombosis in patients undergoing peri-sigmoid posterior fossa surgery in the pre- and post-COVID era and investigate whether COVID infection confers an increased risk of sinus thrombosis.
METHODS: A retrospective review of a single institution case series of patients underwent peri-sigmoid surgery (retrosigmoid, translabyrinthine, or far lateral) approach. Relevant clinical variables were investigated that may confer an increased risk of sinus thrombosis.
RESULTS: A total of 311 patients (178 in the pre-COVID era, and 133 operated on after the pandemic began in March 2020) are included in the study. The composite incidence of sinus thrombosis seen on post-operative imaging was 7.8%. The incidence of sinus thrombosis in the pre-COVID cohort was N = 12 patients (6.7%) versus N = 12 (9%) in the post-COVID cohort (p = 0.46). A history of COVID infection was not shown to confer an increased risk of post-operative sinus thrombosis (OR: 0.61; 95% CI: 0.08-4.79, p = 0.64). Only a small number of patients (N = 7, 2.3%) required either medical or surgical intervention for post-operative sinus thrombosis.
CONCLUSION: The overall incidence of post-operative sinus thrombosis is similar in the pre- and post-COVID era. The findings of this study suggest that COVID infection is not associated with a higher risk of venous sinus thrombosis.
BACKGROUND: Delirium is a common complication in elderly patients after cardiac surgery, and sleep disorders have been suggested as a potential risk factor. However, few studies have explored the link between long-term preoperative poor sleep quality and postoperative delirium (POD) in this population. This study aimed to investigate the association between preoperative sleep quality and POD in elderly cardiac surgery patients.
METHODS: The study enrolled 194 patients aged 60 years or older who underwent cardiac surgery. The Pittsburgh Sleep Quality Index (PSQI) objectively assessed preoperative sleep quality, while the Confusion Assessment Method screened for POD. The measurable outcomes encompassed the identification of risk factors associated with POD, while the secondary outcomes focused on factors influencing levels of consciousness. The statistical analysis is logistic regression analysis.
RESULTS: Patients with POD had a higher prevalence of preoperative sleep disorders and higher PSQI scores than those without delirium (12.9 ± 5.1 vs 7.8 ± 3.4, P = .007). Logistic regression analysis demonstrated that the number of months with high PSQI scores and age were significantly associated with POD. The predictive ability of the number of months with high PSQI scores for POD was .762 (95% CI: .671-.854). Multivariate linear regression analysis revealed that preoperative sleep disorder was a significant predictor of exacerbation of POD (P < .05).
CONCLUSION: This study suggests that long-term poor preoperative sleep quality, as assessed by the PSQI, is associated with an increased risk of POD in elderly patients undergoing cardiac surgery.
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.

Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure.

Loteprednol etabonate is structurally similar to other corticosteroids. However, the number 20 position ketone group is absent.

The anti-infective component in the combination (tobramycin) is included to provide action against susceptible organisms. In vitro studies have demonstrated that tobramycin is active against susceptible strains of the following microorganisms: 

Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species.
Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
This is a Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen.

Part 1, Schedule A will assess the safety and pharmacodynamics of GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. It is estimated that up to 35-45 evaluable subjects will be enrolled in Part 1. Part 2 will explore further the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of the MTD(s) identified in Part 1. A minimum of 15 and maximum of 40 subjects will enroll in Part 2 Safety/Clinical Activity Cohort for each Schedule explored. The Part 2 PK/PD cohort will enroll up to 18 subjects. This pharmacokinetic cohort will explore whether exposure to GSK2110183 at the MTD is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are given by themselves or in combination with GSK2110183. The identified MTD(s) and pharmacodynamic results in this study will inform the doses for future development of the regimen of GSK2110183 dosed in combination with bortezomib and dexamethasone in subjects with relapsed/refractory MM.
<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use having thickening properties at pH6-7.5 in the presence of a salt and even excellent usability.  <P>SOLUTION: This skin care preparation for external use is characterized as follows. An acrylic acid or a methacrylic acid/alkyl (meth)acrylate/(meth)acrylic acid POE (polyoxyethylene) monoalkyl ether ester copolymer is formulated with the salt and the pH is adjusted to 6.0-7.5. The thickening properties can be enhanced by formulating a nonionic surfactant and/or an oil. At least one kind of salt type bleaching agent selected from an ascorbic acid bleaching agent and an alkoxysalicylic acid bleaching agent is cited as the salt.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention provides improved methods for the purification of factor XIII. In particular, the methods provide compositions containing 5% or less contaminating proteins. In particular embodiments of the present invention the methods provide purified factor XIII compositions comprising less than 1% activated factor XIII, less than 2% protein aggregates, and/or less than 5% charge isomers of factor XIII. The methods do not require the use a precipitation or crystallization step common to prior methods of isolating factor XIII. Instead, the method uses immobilized metal affinity chromatography to remove various contaminants common to recombinant expression of factor XIII. Further, a combination of various chromatography methods including ion exchange chromatography, hydrophobic affinity chromatography, and immobilized metal affinity chromatography comprise a simple and less expensive method to produce a pharmaceutical grade factor XIII product at high yield.
This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release. The formed film is characterized by: locally sustained levels of a minimum effective concentration (MEC) of the active agent between applications; its adherence and conformance to a surface of the skin; its pliability, its resistance to breaking under tension (tensile strength); maintained potency of the active agent; and removability of the film from the skin without a residue.
FIELD: biotechnology, molecular biology, genetic engineering. SUBSTANCE: invention reports about novel polypeptides eliciting hemopoietic biological activity of factor of stem cells using genetic engineering methods. Polypeptides are expressed by the host cell carrying DNA-containing vector encoding one of variants of polypeptide. Method allows preparing recombinant polypeptide product as result of expression of DNA sequence. Polypeptides or recombinant polypeptide products are components of pharmaceutical composition used for hemopoietic therapy in mammals. Except for, they can be used for enhancement of effectiveness of genetic therapy, stimulation of early hematopoietic precursor-cells, enhancement of bone marrow grafting in transplantation, enhancement of degree of bone marrow recovery in aplasia treatment or myelosuppression of bone marrow caused by physical-chemical factors. Invention allows preparing polypeptides no occurring in the nature and having sufficiently duplicative amino acid sequences that can replace natural factors of the stem cell. EFFECT: improved preparing method, valuable medicinal properties of polypeptide. 82 cl, 68 dwg, 17 tbl, 20 ex
The present invention relates to an oral care composition and a method of disinfecting the oral cavity. So far synthetic material (e.g. Triclosan) has been used which is believed by many consumers to be harsh on them. Consumers, more and more prefer using products that contain natural materials. Further, in many countries, culturally or otherwise, people are reluctant to using alcohol in their mouthwashes. The present inventors have been working on solving these problems and have come up with an oral care composition which includes natural materials that are found to interact synergistically with certain metal salts in killing  S. mutans , a bacterium responsible for tooth decay.
Twelve male adolescent (13-24 years) subjects with confirmed genetic diagnosis of FraX (full mutation) will participate in this randomized double-blind placebo-controlled study. They will receive a dose of either 24 IU oxytocin, 48 IU oxytocin or placebo at each of three visits to the lab, with each visit spaced one week apart. The efficacy of each dose will be evaluated using behavioral, cognitive and physiological metrics. If individual subject results suggest that either of the oxytocin dosage levels (24 IU or 48 IU) is superior to placebo in the double-blind phase, a single-blind trial using the optimal dosage of oxytocin will then be administered daily for 14 days by parents at home. Subjects will then come into the lab for a final assessment on Day 30. Determination of beneficial response to oxytocin will be based on a 20% change (improvement) in behavior or test performance (see below). If both oxytocin dosage levels provide similar benefits compared to placebo, the lower dose will be chosen for the 14 day single-blind trial.
NEW MATERIAL:A compound of formulaI(X is H, lower alkoxyl or lower alkyl; R<1> and R<2> are lower alkyl) and an acid addition salt thereof. EXAMPLE:4-Benzylidene-2- 4-(2-dimethylaminoethoxycarbonyl)phenyl -1, 3-oxathiolan-5-one. USE:A hypotensive agent. PROCESS:A novel acid halide of formula II(Y is halogen) is reacted with an alcohol of formula III to give an ester derivative of formulaI. The reaction is preferably carried out in a solvent, e.g. tetrahydrofuran (THF) or chloroform, advantageously by using the compound of formula III in an amount about equimolar with the compound of formula II at -20 deg.C-about the boiling point of the solvent.
OBJECTIVES: This study aims to: 1) Explore the mobility experiences of seniors with slow walking speeds (SSWS) in urban neighborhoods; and 2) Investigate their environmental barriers and supports.
METHODS: Go-along interviews were conducted with 36 SSWS residing in urban neighborhoods of Chongqing City, China. The mobility patterns and built environment factors influencing their mobility were revealed through cartographic analysis and thematic analysis.
RESULTS: SSWS primarily focused their activities within a 400-meter radius of their homes. Built environment themes included topography, neighborhood services, sidewalks, seating, traffic safety, weather, greenery, and lighting. Significant mobility barriers included long stairs, steep slopes, fast-moving objects on sidewalks, road crossings, and fast traffic. Available handrails, nearby food-service places, ample seating, and greenery were identified as supportive factors for their mobility.
CONCLUSION: This study stands out as the first to specifically examine the mobility of SSWS within the built environment. We suggest that SSWS should be taken into account when establishing a benchmark for general design frameworks. These improvements not only contribute to the mobility of slow walkers but also have positive impacts on the broader population.
Provided is use of mannose in inhibiting pyroptosis or relieving toxic and side effects of a chemotherapy drug, which relates to the field of medical science and technologies. Mannose inhibits pyroptosis induced by a chemotherapy drug, such that toxic and side effects caused by the chemotherapy drug on the intestinal tract and the kidney are relieved, and meanwhile, a treatment effect of the chemotherapy drug on a tumor is not affected. Mannose can be used for preparing a drug, a kit, a pharmaceutical composition or a health care product for inhibiting pyroptosis or relieving toxic and side effects of the chemotherapy drug. Side effects caused by the chemotherapy drug on the kidney and the intestinal tract can be relieved. Mannose can be used as a supplementary drug clinically, the toxic and side effects of the chemotherapy drug are relieved as much as possible while the curative effect of the chemotherapy drug is ensured, the physical and psychological health of the patient is improved, and meanwhile, the tumor inhibition effect of the chemotherapy drug is not affected. Therefore, a new choice for clinical medication is provided for a cancer patient.
All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
Adults - Two doses of 500 mg each at an interval of 8 to 12 hours. Treatment may be repeated if necessary or extended if required.

In the treatment of complications of gonorrheal urethritis, such as prostatitis and epididymitis, prolonged and intensive therapy is recommended. Cases of gonorrhea with a suspected primary lesion of syphilis should have darkfield examinations before receiving treatment. In all other cases where concomitant syphilis is suspected, monthly serological tests should be made for a minimum of four months.

The doses for the preceding infections may be given by either the intramuscular or intravenous route. A change to oral ampicillin may be made when appropriate.
The invention relates to a domestication method of lactococcus lactis which has the capacity of conversing urea. The invention leads bacteria to gradually adapt to new environment through changing living environment of bacteria, utilizing strong adaptability of bacteria to different environments and gradually domesticating. Bacteria is cultured under the circumstance of gradually changing external conditions, bacterial which does no adapt to new environment dies, and some bacteria can occur variation to adapt to new environment, bacteria which is deduced has stronger endurance lives, new endurance bacterial strain is formed. The method pressurizes and domesticates lactic acid bacteria under the concentration which is close to or higher than the concentration of gastrointestinal urea of patients with uremia, which cultures conversion urea with high efficiency and food-grade lactic acid bacteria which adapts to gastrointestinal environment. Domestication bacteria which are obtained can obviously lower the concentration of urea in a culture medium from 40.01+-1.94mg/dL to 32.99+-3.13mg/dL in 24 hours. And the concentration of urea is further lowered to 25.73+-2.46mg/dL under the circumstance of maintaining culture medium pH and adding nickel salt.
BACKGROUND: Lactate was a prognostic indicator for acute myocardial infarction (AMI) patients. However, the association between normalized lactate load, representing hypoxic burden over time, and in-hospital mortality remained uncertain.
METHODS: The data for this study was obtained from the Medical Information Mart for Intensive Care IV (MIMIC-IV, version 2.1) database. The normalized lactate load, describing the average intensity of hyperlactatemia, was calculated as the area under the curve (AUC) of lactate divided by time. 5882 AMI patients enrolled in this study were divided into survivor (n = 5015), and non-survivor group (n = 867). The primary endpoint was in-hospital mortality. Receiver operating characteristic (ROC) curves were generated to assess the predictive efficacy of normalized lactate load for in-hospital mortality, and areas under the curves of different parameters were compared using DeLong test. Multivariate binary logistic regression analysis was employed to explore the association between normalized lactate load and in-hospital mortality. The adjusting variables included age, gender, ethnicity, heart rate, systolic blood pressure, congestive heart failure, shock, dyslipidemia, cardiac arrest, cerebrovascular disease, neutrophil, lymphocyte, creatinine, blood nitrogen urea, clopidogrel, beta-blockers, angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), statins, dialysis, extracorporeal membrane oxygenation (ECMO), the Sequential Organ Failure Assessment (SOFA) score and Simplified Acute Physiology Score II (SAPS II). Restricted cubic spline (RCS) was conducted to evaluate nonlinear associations of normalized lactate load with in-hospital mortality.
RESULTS: The overall in-hospital mortality rate was 14.7%. After adjusting for confounding variables, normalized lactate load was independently associated with increased risk of in-hospital mortality (Normalized lactate load≥2.6 vs Normalized lactate load<2.6: OR, 95% CI: 1.56, 1.27-1.93). The RCS demonstrated a positive linear relationship between normalized lactate load and in-hospital mortality (non-linear p = 0.725). ROC curves showed that normalized lactate load was better than first lactate, maximum lactate, and mean lactate in predicting in-hospital mortality, but lower than SOFA and SAPS II. Among participants with at least nine lactate measures, normalized lactate load showed predictive performance comparable to SOFA and SAPS II.
CONCLUSION: Normalized lactate load can be used to predict the prognosis of in-hospital mortality in AMI patients, and its prediction performance increases with the increase of lactate measurement.
<P>PROBLEM TO BE SOLVED: To provide a composition and method for modulating the expression of apolipoprotein B.  <P>SOLUTION: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Pharmaceutical compositions and other compositions comprising the compounds are also provided. Methods for modulating the expression of apolipoprotein B in the cells are further provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT